Outcome of Board Meeting held on August 13, 2026 to consider and approve, inter-alia, un-audited financial results of the company for quarter ended June 30, 2026.

BRAWN BIOTECH LTD. August 13, 2026 BSE Limited, Department of Corporate Services, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400001 Scrip Code: 530207 Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Outcome of Board Meeting held on August 13,2026 Dear Sir/ Ma’am, P ( iu L nir fss otu ria mnn gt t h Ot abo tl t i th g he a e t p Bir o oo n av s ri s dai no on d fs D Do iif rs e ct clh toe os rR u se r g e ou fl R a e tt hqi eu o i Cn r o e3 mm0 pe anr t ne sa yd ) , w R ai e tt g h iu t l sR ae mtg i eu o el n ta s it , n i go 2 n 0 h 1 e3 l53 d (a tn “ od dS a Eo yBt ,Ih e i .r L e .ia ,s p Atp uil n gi gc u a sRb tel ge 1 u 3r l ,e a g t 2u i 0l o 2a n 6t si ,”o )n has , s o ,w f e i t n h twe ei r S -s ahE l B it aI o , approved the following: 1. B tha es e qud a o rtn e t rh ee n r de ec do Jm um ne en d 3a 0t , i 2o 0n 2s 6 o af l t oh ne g A wu id ti ht tC ho em lm ii mt it te ee d , r et vhe i eB wo a rer pd o rh ta s t ha ep rp er ono .v e Fd in t ah ne c iU an l- A Reu sd ui lt te sd t F oi gn ea tn hc ei ra wl i R te hs Lul it ms i tf eo dr Review Report are enclosed as Annexure - L 2. B M f fia o n s r aa te nhnd ccd i o ao ln mC i o yt n, eh g ae A rCr h Ge 2ac 0r Mo 2tm 6e fm r -oee 2rdn 7 ad A ta p ict lec li roo tiu hon n eds t a o co n f of t n5 st c ,h lye ue a saA s iru s od nSi c tt ooa t fmC u mo Atm eo Gm r nyi c M t iAt nu te gd oe i , f bt r eot o rh hs me e tB lo h do f e a ir ct nod h e n 2h c 0a lC 3s u 1o s .mr i pe o Dac n e n to o aym f i,m lA e s s Gn aud sMbe j r d e o ec f qtt uh te it h ro ea e p c dap op uo mp ni r p dn o a et v n rm a y e l tn htt o eo f o b Sf em E M e h B/ em Is lb d e L ir i snsG t D t i h naS et g Regulations are enclosed as Annexure - 1L 3. C V noo i tn d is e ci o ed e cCr o oe n nd f v e ea r nn e id n n c ga i p tnp hg er o ( mv V ee C ed ) t / iC O no t gn h v te oe r n bAi eun d ig i s soo u-f eV dt ih s ae u na4 dl1 d % M i seA pan ann ts cu h a e(l dO G tAe oV n te M hr e)a l so hM ane r eTe hut oei lsn ddg ea ryo s,f ft S oh ree p s tM ee ee m km b ib nee grr t2s h9 e , io rf 2 at 0 ph 2 pe 6 r , oC vo a alm lo ,p n a ig nn twy ei r tt ahh l ir ado ,ru a og fh nt matters cited in the Notice of AGM. 4. Considered and approved the Boards' Report for the financial year ended March 31, 2026. T ish e B so a ar vd im le ac blt ei n og c to hm em Ce on mc pe ad s12 w: e3 b0 P itM e. ( wI wS wT .) ra an wd c bo in oc tl eu cd he .d a ot .1. W00 P rM e. u( eI sS tT ) y. T uh te a kf io nr de lm ye n tt ai keo n te hd d ai bsc ol vo es u or ne record. Thanking you, Yours faithfully, For and on behalf of . Brawn Biotech Limi Priyan! e Company Secretary-& Compliance Officer Membership No. A50385 ‘ CIN NO.: L74899DL1985PLC022468 o for Getten e Regd. Office : C-M.' Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331 work Email: solution@brawnbiotech.com orks : Plot .No..44,.F'ac‘e City-1, Sector 37, Near Hero Honda Chowk, Gurugram - 122001, Haryana, INDIA BRAWN BIOTECH LTD. Email: distribution@brawnlabs.in | Website : www.brawngroup.in Annexure-| BRAWN BIOTECH LTD. "BRAWN BIOTECH LIMITED. CINL74899DL19KSPLCO22468 REGD. OFFICE: C-64 Lajpat Nagar-1 Delhi 130024 STAGFT STEANDAMLONE UN-NAUDITT£0 FINANCIAL SF5ULTS FOTR QUARYES EXDED 08 I 2025 bainize S Particolars Quarter Ended Vear Ended No.| 30-Jun-26 [ simMarze | 30qunzs 31-Mar 26 R Unaudited | Audited | Un-audited Audited 1 [Refrvom oopernatieons [Revenue from opecations Go75n 765 7977 5777 [Other ncome 1385 1509 0 540 Total Reveoue o217 21578 ssass 174318 Z [Expenses - = [Cost of materal commumed - - B - b [Purchase ofstckin-trade I Tz ot Ta1Le o |Change i ovetories offished goods worl in progress and stock n trade 29534 e 10492 049 & [Employee Reneft expenses 05 1921 w52 [ o [Depreciaantd iaomnor tistion expenses 259 300 07 1220 T [Finance Cost 0z 023 o3 045 £ [Otherepenses 5390 5748 551 2013 [Totad Expenses 0630 25136 56526 174307 5 [Pralt from Operation befare OFheF Tncome, excepiTana and exia-ordmary. ¢ items (1-2) : 4 1548 (3562 260 om + [Other Income 5 5 F ¥ 5 [Proftfroomr dinary aciivities before exceptieomsn a(3-l9) Taa Ge) P o011 6 [Exceptional ltems 5 B z B 7 |Profit from ordinary activities before tx (56) B [E] Z0 o1 8 [Tax Expenses (5355) ©395) 9 [Proft (Loes) for the period from contimuling operatio(7n8s] a1 EE P 05 T0 [Profitf/r(omi odiswcosnt)in uing operations = s B B 11 [Tax expense of discontinuing operatiuns - - - 5 2 [Profit/ (o) from Disconfinuing operations (@ier tax) (10-11) - - - 5 13 [Profit (Loss) for the period (9+12) ma1 EED B0 405 12 [Other Comprehensive Income 009 08 220 365 [Total Comprensive Income 553 Sea1 2680 5771 T [Detals ofeqshaire ctapiytal S0 20003 30003 S0003 [Paeqiuiyd sha-re uapiptal [Face value of cquity share copl] T |Reserve exchuing Revaluation Reserve 17 [Earnpiern shgarse 1 [Rasic carnings pershare 052 185 [ 53 052 15 089 32 1 Reitsforthe quarter ended an 30th June, 2028 wer reviewed by the Audit comnitiee and then 3pprove by the Board of Directorsattheir meeting held on 13th August, 2025, 2 The Statutory Aufors caifed aut the [t review for quarter ended 30th June, 2025, The management has esercised esessary due diigence to ensurs Uhat the financal resuls provided| atrue and fait vew of 1 affaivs. 3 The abive reslts have been prepared in complisnce with the recogeition and measusement princples of the Companies {Indian Accunting Standards) Rules, 2015 ind AS), 25 amended byl the Companies (ncian Accounting Standards) [Amendment rles), 2015 prescribed under Section 133 of the comparies Act, 2013 and other reccgaiced a<couring practices and policies tol the xtent appiicable The Company is ngaged primarly i the business of Phatmaceuticals. Accordingly, here s o separate reportable segrments as per Ind-AS 108 dealing with Operating Segments. The sbove Standalane Un- audited Finandal Resuls for the quarter ended on 30062026 are svalable on company's Webs & www brawbiotech com and BSE website| v bseindia com. Preyeavr / ipiood fuguress . been regronped cearranged, whereer necessary tomake them comparsble with the current period igures. For and on behalf of Board For Brawn Biotech Limited Place: Delhi ‘ CIN NO.: L74899DL1985PLC022468 oo for betten life Warks : Plot No. 85, Basement & Ground Floor, Pace City-1, Sector-37, Gurugram, Haryana- 122001, INDIA ' Emal: distribution@brawnlabs.in | Website : www.brawngroup.in o\ Regd. Office : C-64, Lajpat Nagar-1, First Floor, New Delhi-110024, INDIA Tel.: 011-29815331 BRAWN BIOTECH LTD. Email: solution@brawnbiotech.com RAJIV UDAI & ASSOCIATES CHARTERED ACCOUNTANTS INDIA The Board of Directors of Brawn Biotech Limited We have reviewed the accompanying statement of unaudited financial results of Brawn Biotech Limitedfor the quarter ended 30" June 2026. This statement is the responsibility of the Company’s Management and has been approved by the Board of Directors. Our responsibility is toiissue a report on these financial statements based on our review. This Statement, which is the responsibility and approved bythe Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting” ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the revietwo obtain moderate assurance as to whethethre financial statements are free of material misstatement. A review is lim [Showing first 8,000 characters — download PDF for full document]